Zanubrutinib with antibody and lower-dose chemo for Waldenström's
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new pill (zanubrutinib) combined with a short course of antibody therapy and a lower dose of chemo for people with Waldenström's macroglobulinemia who haven't had strong treatment before. The goal is to see if this gentler combination can control the disease well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 18 years or older
- Diagnosis of Waldenström's macroglobulinemia that hasn't been treated with strong chemotherapy yet
- Must have symptoms or lab signs that show treatment is needed (like low blood counts, fever, night sweats, or large lymph nodes)
- Must be in good enough health to walk and take care of yourself (ECOG score 0-2)
- Must have adequate kidney and liver function, and blood counts not too low
- Cannot have HIV, active hepatitis B, other active cancers, or be pregnant or nursing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests switching from ibrutinib alone to a short course of bendamustine and rituximab (BR) for Waldenström Macroglobulinemia patients who had a good response to ibrutinib but did not achieve complete remission. The goal is to see if the switch can deepen the response without causing severe side effects.
This trial tests a combination of two drugs, zanubrutinib and BR (bendamustine and rituximab), as a first treatment for people with Waldenström's macroglobulinemia. The goal is to see if this combination works better than standard treatment.
This Phase 2 trial studies zanubrutinib combined with BR (bendamustine and rituximab) in adults newly diagnosed with Waldenström macroglobulinemia (WM) who have symptoms. It may help shrink the abnormal disease and improve symptoms like high blood stickiness, nerve problems, anemia, and other lymphoma-related issues.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial tests a combination of two targeted drugs, zanubrutinib and BGB-11417, for people with Waldenström Macroglobulinemia who have already had at least one prior treatment. The goal is to see if this two-drug approach works better than standard options.
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
Hear when a new Waldenström Macroglobulinemia (WM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.